Compare AI & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AI | OCUL |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.2B |
| IPO Year | 2020 | 2014 |
| Metric | AI | OCUL |
|---|---|---|
| Price | $10.15 | $9.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 10 |
| Target Price | $20.00 | ★ $22.56 |
| AVG Volume (30 Days) | ★ 7.3M | 5.7M |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $352,913,000.00 | $55,783,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.36 | $11.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.84 | N/A |
| 52 Week Low | $10.19 | $5.79 |
| 52 Week High | $35.98 | $16.44 |
| Indicator | AI | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 27.27 | 33.08 |
| Support Level | $10.19 | $8.36 |
| Resistance Level | $11.13 | $11.13 |
| Average True Range (ATR) | 0.71 | 0.72 |
| MACD | -0.22 | -0.17 |
| Stochastic Oscillator | 3.75 | 18.97 |
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.